News | Neuro Imaging | January 04, 2017

MRI Scans Detect 'Brain Rust' in Schizophrenia

New magnetic resonance spectroscopy technique offers better visualization of the biology of schizophrenia and other mental illnesses

brain rust, MRI, schizophrenia, American College of Neuropsychopharmacology, ACNP, Fei Du

January 4, 2017 — A damaging chemical imbalance in the brain may contribute to schizophrenia, according to research presented at the American College of Neuropsychopharmacology Annual Meeting, Dec. 4-8 in Hollywood, Fla.

Using a new kind of magnetic resonance imaging (MRI) measurement, neuroscientists reported higher levels of oxidative stress in patients with schizophrenia, when compared both to healthy individuals and those with bipolar disorder.

"Intensive energy demands on brain cells leads to accumulation of highly reactive oxygen species, such as free radicals and hydrogen peroxide," according to the study's lead investigator, Fei Du, Ph.D., an assistant professor of psychiatry at Harvard Medical School. In schizophrenia, excessive oxidation — which involves the same type of chemical reaction that causes metal to corrode into rust — is widely thought to cause inflammation and cellular damage. However, measuring this process in the living human brain has remained challenging.

Du and colleagues at McLean Hospital measured oxidative stress using a novel magnetic resonance spectroscopy technique. This technique uses MRI scanners to non-invasively measure brain concentrations of two molecules, NAD+ and NADH, that give a readout of how well the brain is able to buffer out excessive oxidants.

Among 21 patients with chronic schizophrenia, Du observed a 53 percent elevation in NADH compared to healthy individuals of similar age. A similar degree of NADH elevation was seen in newly diagnosed schizophrenia, suggesting that oxidation imbalance is present even in the early stages of illness. More modest NADH increases were also seen in bipolar disorder, which shares some genetic and clinical overlap with schizophrenia.

In addition to offering new insights into the biology of schizophrenia, this finding also provides a potential way to test the effectiveness of new interventions. "We hope this work will lead to new strategies to protect the brain from oxidative stress and improve brain function in schizophrenia," Du concludes.

This work was supported by grants from MH092704 (F.D.); NARSAD (F.D.); NARSAD (D.O.); MH094594 (D.O.); MH104449 (D.O.); Shervert Frazier Research Institute (B.M.C.).

For more information: www.acnp.org

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...